SynuCa Therapeutics

Innovative disease modifying treatment for Parkinson's patients 

Innovative disease modifying treatment for Parkinson's patients

SynuCa Therapeutics combines decades of groundbreaking research in P-type ATPases and neuroscience from Aarhus University to propose a novel disease-modifying treatment for patients suffering from Parkinson's Disease and associated disorders.

By targeting the SERCA calcium transporter, our first-in-class small molecules salvage the root disease cause by repairing the neuronal calcium imbalances caused by pathological α-Synuclein brain species.

Photo: Esben Zøllner Olesen for BioInnovation Institute

Management 


Lasse Reimer

CEO/Founder 


William Dalby Brown 

COO/founder 

 Professor Poul Henning Jensen

Founder 

Professor Claus Elsborg Olesen

Founder